
MAX BioPharma is developing proprietary lipid based therapeutics for osteoporosis, localized bone growth (multiple applications) and pancreatic cancer.
Leveraging combined expertise in the fields of cellular biology, lipid biochemistry and drug discovery, MAX BioPharma is building a new generation of therapeutic agents that can address unmet medical needs with some of the most fatal and debilitating human disorders, like osteoporosis and pancreatic cancer. The company has developed a number of oxysterol small molecules that regulate normal physiology and disease and are excellent candidates for further therapeutic development.
Graduated in 2018
Location: Santa Monica, CA
Contact:
www.maxbiopharma.com
Graduated Companies
- Adaptix
- Aneeve
- Aneuvo
- Appia Bio
- Bluefin Foods
- CarbonBuilt
- Carbonics
- Charlot Biosciences
- CBD Research Institute
- Cellmic
- Concrete-AI
- Craytex
- CytoLumina
- DARTS Sciences
- Electronucleics
- EP Dynamics
- Ferrologix
- Horizon PV
- Inspira
- Inston
- InvVax
- Kelvi
- Keyssa
- Kythera Biopharmaceuticals
- Librede
- Lucendi
- Matrix Sensors, Inc.
- MAX BioPharma
- MediSens Wireless
- MicrobeDx
- Millibatt
- MyoGene Bio
- Myst Therapeutics
- Nammi Therapeutics
- NanoClear
- NanoElectronic Imaging
- NanoH₂O
- Nanopixel Technologies
- National Institute of Cannabinoid Research (NICR)
- Octant
- Omega Biosystems
- Orchard Therapeutics
- Polyradiant
- Qwixel Therapeutics
- Restore Technologies
- Sardona Therapeutics
- SELFA
- Sixal
- Spectradyne Particle Analysis
- Tempo Therapeutics
- TrueCath
- U-Defi
- Valerion Therapeutics
- Vivibaba
- Zenomics
- Back to Portfolio